




EUROPEAN CURRICULUM VITAE



INFORMATION

Name Elena Tenti
Address Via Corriera 1, Cotignola (Ravenna) Italy
Mobile +39 339 1572707
E- mail etenti@gvmnet.it
Nationality Italian

WORK EXPERIENCE

Dates From Aug 2018
Name and address of employer Maria Cecilia Hospital, GVM Care & Research
Via Corriera 1, Cotignola ,Ravenna
Type of business or sector Clinical Research
Occupation **Head of Clinical Trial Unit**
Main activities and responsibility Promoting and facilitating leading-edge research, including collaborative and interdisciplinary research. Developing strong linkages with departments and units. Leading strategic planning for the research centre to ensure that the centre's objectives are aligned with the research plan objectives; overseeing the proper discharge of administrative duties of the research centre.

Dates From Nov 2015 to Jul 2018
Name and address of employer Institute of Haematology "L. and A. Seràgnoli", S. Orsola- Malpighi
Via Massarenti 9, Bologna
Type of business or sector Clinical Research
Occupation **Clinical Project Manager**
Main activities and responsibility Management of clinical trials in the context of Acute Leukemias. Coordination with Principal Investigator and department, to help ensure that clinical research and related activities are performed in accordance with National regulations and University and sponsoring agency policies and procedures. Cooperation with University compliance and monitoring efforts related to sponsored program administration and reports instances of noncompliance to the appropriate compliance office. Preparation and control of research budgets and financial payments. Attendance at conferences and writing of scientific articles.

Dates From Jan 2012 to Jul 2015
Name and address of employer IRST IRCCS - Cancer Center
Via P. Maroncelli 40 – Meldola (Forlì)

Type of business or sector	Sciences and Oncology
Occupation	Pharmacovigilance Manager
Main activities and responsibility	Collection and assessment of safety related information to determine the benefit/risk impact. Implementing risk management strategies to minimise risks associated with medicines use. Communication of any risk to HCPs. Assessing the effectiveness of pharmacovigilance activities Attendance at conferences and writing of scientific articles.
Dates	From Aug 2010 to Dec 2011
Name and address of employer	Local Health Department of Cesena (AUSL) P.zza Leonardo Sciascia 111, Cesena
Type of business or sector	Healthcare
Occupation	Pharmacovigilance Manager
Main activities and responsibility	Improvement of patient adverse drug reactions (ADR) reporting, monitoring the safety of medicines used off-label, monitoring of vaccine adverse drug reactions. Collection of data that be useful in pharmacoepidemiological studies. Attendance at conferences and writing of scientific articles.
Dates	From Sep 2009 to Sep 2012
Name and address of employer	University of Bologna, Food Science Campus (Cesena)
Type of business or sector	University and Research
Occupation	Contract Professor
Main activities and responsibility	Knowledge and understanding on the main concepts of Inorganic Chemistry
Dates	From Sep 2006 to Jun 2009
Name and address of employer	Technical Institute
Type of business or sector	Education
Occupation	Chemistry Professor
Main activities and responsibility	Education and practical laboratory training
Dates	From Feb 2005 to Feb 2006
Name and address of employer	Private Pharmacy
Type of business or sector	Healthcare
Occupation	Pharmacist
Main activities and responsibility	Dispensing or supervising the dispensation of medications and related supplies, according to physicians' prescriptions. Reviewing prescriptions for accuracy. Checking for drug interactions. Compounding medications and preparing special solutions. Overseeing daily ordering, as well as automatic refills. Collaborating with other healthcare professionals to plan, monitor, review, and evaluate patient effectiveness
Dates	From nov 2003
Name and address of employer	University of Urbino - P. zza Rinascimento 1, Urbino (PU)
Type of business or sector	University and Research
Occupation	PhD Fellowship
Main activities and responsibility	Design and synthesis of a novel class of high-affinity MT2-selective melatonin receptor ligand

EDUCATION

Dates From Mar 2013 to Jan 2014
Name and type of organization University of Milan
providing education and training Faculty of Pharmacy
Principal occupational skills covered Innovative Therapies in Oncology, new pharmacotherapeutic approaches in oncology and biotechnology; Pharmacotoxicology, Oncology
Title of qualification II level **Master in Oncology Pharmacy and Pharmacology**

Dates From Jan 2009 to Jan 2010
Name and type of organization University of Modena- Reggio Emilia
providing education and training Department of Oncology, Hematology and Pathology
Principal occupational skills covered Statistical methodology of randomized controlled trials
Title of qualification **Advanced Course in Statistics**

Dates From 1993/94 Academic year to 2001/2002 Academic year
Name and type of organization University of Bologna
providing education and training Faculty of Pharmacy
Principal occupational skills covered Biochemistry, Pharmacology, Pathology, Pharmaceutical Chemistry, Toxicology, Molecular Biology
Experimental Thesis in Biochemistry: Protein folding intermediates revealed by intrinsic fluorescence quenching measurements
Title of qualification awarded **Degree in Chemistry and Pharmaceutical Technologies**

Dates From Sep 1988 to Jul 1993
Name and type of organization Scientific High School A. Oriani
providing education and training Via Oberdan, Ravenna (Ra)
Principal occupational skills covered Mathematics, Physics, Chemistry
Title of qualification awarded **Scientific High School Diploma**

PROFESSIONAL TRAINING

29 May 2023 Artificial Intelligence in healthcare, AUSL Romagna
27 May 2022 Antithrombotic therapy, Maria Cecilia Hospital
03 May 2022 Prevention of cardiovascular disease in woman, Maria Cecilia Hospital
07 Feb 2020 Leadership Empowerment, Maria Cecilia Hospital
24 Jul 2019 R&D Projects, Maria Cecilia Hospital
16 Jul 2019 Joint Commission International, Maria Cecilia Hospital
5 Mar 2019 UNI ISO 201387:2018 Biotechnology – Biobanking, UNI Milano
30 Aug 2017 ICH Good Clinical Practice E6 (R2) – Global Health Training Center

30 May 2017	Adverse Drug Reaction: reporting makes medicines safety- European Union of Medical Specialists
17 Nov 2016	Affymetrix GeneChip: applications for clinical research, Bologna
20 Oct 2016	Next in Leukemia, pre SIES, Waldorf Hotel Rimini
19/21 Oct 2016	SIES Annual Meeting (Italian Society of Experimental Hematology)
07/08/09 May 2014	3 rd International Conference “Translational Research in Oncology: a new Approach to Personalized Medicine” – IRST IRCCS Cancer Center, Meldola (FC)
22 Jan 2013	Toxicity of targeted oncology drugs: incidence, clinical patterns, treatment, possible prevention, biological models IRST IRCCS Cancer Center, Meldola (FC)
14 Dec 2012	6th Course of Regional Pharmacovigilance for Pharmacists: systematic exploration of the scientific literature- Regione Emilia Romagna (BO)
12/13/14 Nov 2012	Theoretical and Practical Course on Clinical Trials in Oncology: from Design to Conduct Study- IRST IRCCS Cancer Center, Meldola (FC)
10/11 Dec 2012	Theoretical/practical writing of protocols and scientific articles Consorzio Mario Negri Sud.
08-09-10-11-May 2012	2 nd International Conference “Translational Research in Oncology: a new Approach to Personalized Medicine” – IRST IRCCS Cancer Center, Meldola (FC)
03 Apr 2012	Chemotherapy: a process at high risk – MIP, School of Management, Politecnico di Milano
27 Mar 2012	Safety in Clinical Trials – University Clinical Hospital of Modena
01 Mar 2012	Pharmacovigilance advanced course – Clinical aspects by Boeringher IRST IRCCS Cancer Center, Meldola (FC)
22/23 Feb 2012	3 ^o Regional Pharmacovigilance course for Oncology Pharmacists- Regione Emilia Romagna
25/26 Oct 2011	5 ^o Regional Pharmacovigilance course for Pharmacists: Pharmacoepidemiology studies - Regione Emilia Romagna
12/13/14 Sept 2011	Adr reported from non conventional medicines, Istituto Superiore di Sanità
30 Mar 2011	Chemical, physical and biological security Management Bufalini Hospital, Cesena
24 Feb 2011	MICROMEDEX and use of database- Bufalini Hospital, Cesena
10 Jan 2011	Course on Clinical Risk Management –Bufalini Hospital, Cesena

TEACHING

From Sep 2013 to 2018	University of Bologna – Faculty of Medicine and Surgery, Master Professor, Professional Master in Nutrition and Health Education
Oct 2020	Clinical Research Management, GVM Campus
Feb 2021	Vaccine Surveillance Management, GVM Campus
Feb 2022	Protocol writing in Clinical Research , GVM Campus

ORAL COMMUNICATION

- Clinical Trial Methodology, Maria Cecilia Hospital, Cotignola, Italy
- Clinical Trial Management, Maria Cecilia Hospital, Cotignola, Italy
- Next in Leukemia. Inotuzumab Ozogamicin protocol: VOD prevention with defibrotide, Milan, Italy
- Next generation sequencing for BCR-ABL KD mutation screening in Philadelphia chromosome positive leukemias, University of Bologna Italy
- Next generation sequencing for BCR-ABL KD mutation screening in Philadelphia chromosome positive leukemias, Naples , Italy
- 20th World Congress on Advances in Oncology, Athens Greece
- Cancer and Food IRST IRCCS Cancer Center
- 3th ISoP Annual Meeting "The Renaissance of Pharmacovigilance" Pisa, Italy
- Oncology Pharmacovigilance International Conference IRST IRCCS Cancer Center
- I Oncology Pharmacovigilance Conference (Multicentric Project) IRST IRCCS Cancer Center
- Pharmacovigilance in Clinical Trials (Profit and no-profit) IRST IRCCS Cancer Center

SCIENTIFIC SEGRETARIAT

15/16 Dec 2017	3° Meeting Next in Leukemia: an educational roundtrip for young hematologists: NGS and surround, University of Bologna
28/29 Nov 2017	Next Generation Sequencing Practical Course, University of Bologna
02 Oct 2017	IDH2 positive Leukemias: a new entity, Roma GIMEMA
15 Sep 2017	Next Generation Sequencing in hematology (in collaboration with Sophia Genetics and Arrow Diagnostics), University of Bologna
01 Mar 2017	2° Investigator Meeting Next In Leukemia, Milan

02 Feb 2017

1° Investigator Meeting Next in Leukemia, Milan

26 Sep 2016

Making Access to Personalized Medicines: a reality for patients (in collaboration with EAPM European Alliance for Personalized Medicine), Aula Absidale S. Lucia, Bologna

PERSONAL SKILLS AND COMPETENCES

Mother tongue

Italian

Other Languages

English German French

Reading skills Excellent Good Elementary

Writing skills Excellent Good Elementary

Verbal skills Excellent Good Elementary

Social skills and competences Recognized as enthusiastic and dynamic professional, results oriented with strong technical experience. Team player with proven ability to manage new project in clinical research and development.

Technical skills

Microsoft Office

STATA -Data analysis and Statistical Software

MICROMEDEX Medication, Disease and Toxicology Management

UpTo Date (evidence-based clinical decision support)

PROFESSIONAL SOCIETIES

Associate Editor of Hematology Reports

Review Editor of Frontiers in Medicine

Expert Consultant of AIFA (Italian Agency of Drug) from March 2012

Member of the Editorial Board of the Italian Society of Hospital Pharmacists (SIFO)

Member Italian Society of Hospital Pharmacists (SIFO)

Registered at the Order of Pharmacists of Ravenna

BIBLIOGRAPHY

- **Albumin Thiolation and Oxidative Stress Status in Patients with Aortic Valve Stenosis.**

Savini C, **Tenti E**, Mikus E, Eligini S, Munno M, Gaspardo A, Gianazza E, Greco A, Ghilardi S, Aldini G, Tremoli E, Banfi C.

Biomolecules. 2023 Nov 28;13(12):1713

- **Post-Operative Delirium and Cognitive Dysfunction in Aged Patients Undergoing Cardiac Surgery: A Randomized Comparison between Two Blood Oxygenators.**

Mantovani L, Mikus E, **Tenti E**, Sangiorgi D, Zannoni S, Cavallucci A, Ferroni L, Cimaglia P, Tolio V, Tremoli E, Savini C.
Bioengineering (Basel). 2023 Dec 15;10(12):1429

- **Less Is More? Combined Approaches to Improve Mortality and Morbidity after Aortic Valve Replacement**

E. Mikus, M. Fiorentino, D. Sangiorgi, S. Calvi, **E. Tenti**, A. Cavallucci, E. Tremoli, A. Tripodi, M. Pin and C. Savini
Biomedicine 2023, 11, 2989

- **A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study**

Pascale, R., Maccaro, A., Mikus, E., Baldassarre M, Tazza B, Rinaldi M, **Tenti E**, Ambretti S, Albertini A, Viale P, Esposito F, Giannella, M., Bartoletti, M.
Journal of Global Antimicrobial Resistance, 2022, 30, pp. 390–394

- **Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial**

Perrone, F., Piccirillo, M.C., Ascierio, P.A., ...Maccari, D., Baciù, I.
Journal of Translational Medicine, 2021, 19(1), 442

- **Pacemaker need after sutureless aortic valve replacement: the role of the learning curve**

Mikus E, Calvi S, Tavazzi L, Brega C, Tripodi A, Pin M, Manfrini M, Zucchetta F, **Tenti E**, Albertini A.
J Cardiovasc Med 2020 Oct 5

- **Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study**

Soverini S, Bavaro L, ... **Tenti E**, Rosti G, Bacarani M, Cavo M, Martinelli G.
Blood. 2019 Dec 26. doi: 10.1182/blood.2019002969.

- **Clinical experience with dalbavancin for the treatment of deep sternal wound infection**

Bartoletti M, Mikus E, Pascale R, Giannella M, Tedeschi S, Calvi S, **Tenti E**, Tumietto F, Viale P.
J Glob Antimicrob Resist. 2019 Mar 26. pii: S2213-7165(19)30084-0.

- **Electronic Capturing of Genetic and Molecular Data in Modern Clinical Trials**

Tenti E, Manfrini M, Zavan B, Balla C and Ferrari R
J Mol Genet Med 2018, 12:4

- **Aneuploidy: cancer strength or vulnerability?**

G. Simonetti, S. Bruno, A. Padella, **E. Tenti**, G. Martinelli
International Journal of Cancer 2019, 144 ; 8-25

- **Leucemia Linfoblastica Acuta Ph1+**

Tenti E., Martinelli G.
Seminari di Ematologia Clinica 2017 Jul 5, ISSN 2838-2839

- **Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML**
Tenti E., Papayannidis C, Marconi G, Parisi S, Simonetti G, Paolini S, Sartor C, Ottaviani E, Testoni N & Giovanni Martinelli
Expert Opin Pharmacother. 2016 Dec;17(18):2479-2486.
- **Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions**
C. Gardini A, *Tenti E.*, Masini C, Nanni O, Scarpi E, Valgiusti M, Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori D, Minguzzi M, Frassinetti GL. *Oncotarget.* 2016 Apr 22. doi: 10.18632
- **Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer**
Passardi A., Scarpi E., Cavann L., Dall'Agata M., Tassinari D., Leo S., Bernardini I., Gelsomino F, Tamperi S., Brandes A., *Tenti E.*, Vespignani R., Frassinetti G. L., Amadori D., De Giorgi U.
Oncotarget – April 21 2016
- **ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study**
A. Casadei Gardini · G. Marisi · L. Faloppi · E. Scarpi · F.G. Foschi · M. Iavarone · G. Lauletta · J. Corbelli · *E. Tenti* · F. Facchetti · C. della Corte · S. Tamperi · S. Cascinu · M. Scartozzi · D. Amadori · O. Nanni · P. Ulivi · G.L. Frassinetti
Oncotarget – April 2016 DOI: 10.18632
- **Effects of metformin on clinical outcome in advanced HCC patients receiving sorafenib**
Casadei Gardini A., Marisi G, Scarpi E., Scartozzi M., Faloppi L., Silvestris N., Masi G., Vivaldi C., Tamperi S., Foschi F. G., Tamburini E., *Tenti E.*, Ricca Rosellini S., Ulivi P., Cascinu S., Nanni O., Frassinetti G.L.
Expert Opinion on Pharmacotherapy DOI 10.1517/14656566.2015.1102887
- **Use of non conventional medicines by cancer patients**
E. Tenti, A. Casadei Gardini, O. Nanni, F. Foca, S. Cumero
European Journal of Oncology EJO Vol 19,2014, Issue 3, 144-149
- **Increase of reports of suspected adverse drug reactions in oncology**
E. Tenti, A. Casadei Gardini, L. Frassinetti, D. Amadori, M. Minguzzi
International Journal of Pharmacy and Pharmaceutical Sciences 2014 Vol 6, Issue 9, 95-96
- **Long term complete response in patient with liver metastases from breast cancer treated with metronomic chemotherapy**
Ceconetto L., Casadei Gardini A., *Tenti E.*, Maltoni R., Bravaccini S., Oboldi D. , Zoli W. , Serra P., Donati C., Sarti S and Rocca A.
Tumori - A Journal of Experimental and Clinical Oncolog 2014;100(3):e79-e82
- **Separate episodes of capillary leak syndrome and pulmonary hypertension in patients treated before with gemcitabine and after with nab-paclitaxel: a case report**
Casadei Gardini, M. Aquilina, D. Oboldi, A. Lucchesi, S. Carloni, *E. Tenti*, M.A. Burgio, D. Amadori, G. Luca Frassinetti
BMC Cancer 2013, 13:542
- **Pediatric Pharmacovigilance signals in the AUSL of Cesena. Analysis of the severity of the reactions reported**
Tenti E., Baraghini M.,

• **Importance of the Pharmacist in monitoring drug prescriptions and reporting children ADRs”**
E. Tenti

Bollettino SIFO 2011 57;(5):255-259

Abstract and conference proceedings

• **Minimally Invasive Combined Mitral And Aortic Valve Surgery**

Mariafrancesca Fiorentino, Elisa Mikus, Alberto Tripodi, Diego Sangiorgi, Simone Calvi, **Elena Tenti**, Fabio Zucchetta, Carlo Savini.

ISMICS, INTERNATIONAL SOCIETY FOR MINIMALLY INVASIVE CARDIOTHORACIC SURGERY, 2023 Annual Scientific Meeting ▪ 31 May – 03 June, 2023 Omni Boston Hotel at the Seaport ▪ Boston, MA, USA

• **Minithoracotomy Approach For Mitral Valve Redo Surgery**

Mariafrancesca Fiorentino, Elisa Mikus, Alberto Tripodi, Diego Sangiorgi, Simone Calvi, **Elena Tenti**, Marco Panzavolta, Francesco Tizzano, Carlo Savini.

ISMICS, INTERNATIONAL SOCIETY FOR MINIMALLY INVASIVE CARDIOTHORACIC SURGERY, 2023 Annual Scientific Meeting ▪ 31 May – 03 June, 2023 Omni Boston Hotel at the Seaport ▪ Boston, MA, USA

• **Mitral Valve Re-repair Through A Right Minithoracotomy**

Elisa Mikus, Simone Calvi, Mariafrancesca Fiorentino, Alberto Tripodi, Diego Sangiorgi, Maurizio Pin, Carlotta Brega, **Elena Tenti**, Carlo Savini

ISMICS, INTERNATIONAL SOCIETY FOR MINIMALLY INVASIVE CARDIOTHORACIC SURGERY, 2023 Annual Scientific Meeting ▪ 31 May – 03 June, 2023 Omni Boston Hotel at the Seaport ▪ Boston, MA, USA

• **Dalbavacin for the treatment of the deep sternal wound**

Tenti Elena, Mikus Elisa, Bartoletti Michele

Istituto Superiore di Sanità, XXVIII Seminario Nazionale ISSN: 0393-5620

• **Establishing a National Network of laboratories using Next Generation Amplicon deep Sequencing for BCR-ABL1 kinase domain mutation screening: the ‘Next in CML’ Study**

Soverini, S; De Benedittis, C; Bavaro, L; Martelli, M ; Stella, S; Iurlo, A, Orofino, N; Barate, C; Galimberti, S; Sica, S; Sora, F; Rossi, AR; Albano, F; Ciceri, F ; Lunghi, F; Castagnetti, F; Gugliotta, G; **Tenti, E**; Rosti, G; Papayannidis, C; Stagno, F; Vigneri, P; Serra, A; Saglio, G; Carnuccio, F; Pane, F; Errichiello, S; Annunziata, M; Breccia, M (; Abruzzese, E; Bonifacio, M; Novella, E; Di Bona, E; Sancetta, R; Calistri, E; Spinosa, G; D'Adda, M; Capodanno, I ; Baccarani, M; Cavo, M; Martinelli, G

Haematologica Oct 2017 Volume: 102 Supplement: 2

• **A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetic Drug or Combination**

Nanni J, Simonetti G, Marconi G, Fontana MC, Bruno S, Papayannidis C, Padella A, Abbenante M, Lo Monaco S, **Tenti E**, Sartor C, Parisi S, Martinelli G

Blood (2017) 130 (Supplement 1): 4969.

- Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and Tyrosine kinase Domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML)**

C. Papayannidis, M.T. Bochicchio, G. Marconi, G. Simonetti, A. Padella, V. Robustelli, M.C. Abbenante, C. Venturi, S. Parisi, S. Paolini, C. Sartor, S. Lo Monaco, A. Ghelli Luserna di Rorà, **E. Tenti**, M.C. Fontana, E. Ottaviani, G. Martinelli
Haematologica Oct 2017, 102 (s3) 1-217
- Prognostic significance of alterations of pathways regulating autophagy in Acute Myeloid Leukemia**

G. Marconi, MC Fontana, C. Papayannidis, A. Padella, S. Lo Monaco, MC Abbenante, C. Sartor, L. Bertamini, J. Nanni, A. Ghelli Luserna di Rorà, V. Robustelli, **E. Tenti**, E. Fonzi, G. Simonetti, E. Ottaviani, C. Baldazzi, N. Testoni, G. Martinelli
J Clin Oncol 35, 2017 (suppl; abstr 7038)
- Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience**

C Papayannidis, S Paolini, A Santoro, V Robustelli, S Soverini, C De Benedittis, E Imbrogno, C Terragna, A Ghelli Luserna Di Rora, S Parisi, C Sartor, G Marconi, S Lo Monaco, MC Abbenante, M C Fontana, A Padella, A Ferrari, G Simonetti, **E Tenti**, F Frabetti, F Volpato, C Baldazzi and G Martinelli
Blood 2016 128:5191
- Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis**

Padella A, Simonetti G, Manfrini M, Fontana MC, Marconi G, Ferrari A, Faria do Valle I, Garonzi M, Papayannidis C, Franchini E, Zuffa E, Guadagnuolo V, Bruno S, **Tenti E**, Baldazzi C, Ottaviani E, Testoni N, Remondini D, Delledonne M, Martinelli G
Blood 2016 128:1677;
- Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)**

G Marconi, C Papayannidis, M C Fontana, A Padella, G Simonetti, M Manfrini, A Ferrari, E Franchini, S Paolini, S Parisi, C Sartor, M C Abbenante, S Lo Monaco, F Volpato, **E Tenti**, V Guadagnuolo, M Perricone, MT Bochicchio, A Ghelli Luserna Di Rora, C Baldazzi, V Robustelli, N Testoni, S Soverini, E Ottaviani and G Martinelli
Blood 2016 128:1679;
- Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations**

M C Fontana, G Marconi, J D. Milosevic Feenstra, C Papayannidis, M Manfrini, V Guadagnuolo, Gi Simonetti, A Padella, A Ferrari, E Franchini, A Ghelli Luserna di Rorà, E Ottaviani, R De Tommaso, S Bruno, S Soverini, N Testoni, S Paolini, C Sartor, S Parisi, **E Tenti**, R Kralovics and G Martinelli
Blood 2016 128:1678;
- The addition of Gemtuzumab Ozogamicin (GO) to intensive chemotherapy significantly improves complete response CR rates and overall survival in patients with newly diagnosed acute myeloid leukemia**

Sartor, C; Papayannidis, C; Candoni, A; Malagola, M; Marconi, G; **Tenti, E**; Manfrini, M; Simonetti, G; Zuffa, E; Abbenante, MCI ; Parisi, S Paolini, S Lo Monaco, S; Franchini, E; Ottaviani, E; Fontana, MC; Padella, A; Guadagnuolo, VI; Fanin, R; Russo, D; Martinelli, G
HAEMATOLOGICA Volume: 101 Supplement: 1 Pages: 219-219 JUN 2016

- **Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)**

Marconi G, Papayannidis C, Fontana MC, Padella A, Simonetti G, Manfrini M, Ferrari A, Franchini E, Paolini S, Parisi S, Sartor C, Abbenante MC, Lo Monaco S, Volpato F, *Tenti E*, Guadagnuolo V, Perricone M, Bochicchio MT, Ghelli A, Baldazzi C, Robustelli V, Testoni N, Soverini S, Ottaviani E, Martinelli G.

ASH Annual Meeting 2016, American Society of Hematology San Diego, CA, Conference: 12/2016

- **Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO)**

C. Papayannidis, A.Candoni, M. Malagola, G. Marconi, *E. Tenti*, M. Manfrini, G. Simonetti, E. Zuffa, MC Abbenante, S. Parisi, S. paolini, C. Sartor, E. Franchini, E. Ottaviani, MC Fontana, A.Padella, N. Testoni, F. Volpato, S. Lo Monaco, R. Fanin, D. Russo, G. Martinelli

ASCO 2016 J Clin Oncol 34, 2016

- **Pharmacological interactions and side effects in oncohaematology: a retrospective observational study**

E. Tenti · A. Casadei Gardini · C. Papayannidis · G. Marconi · G. Simonetti · S. Parisi · S. Paolini · C. Sartor · E. Ottaviani · C. Venturi · M. C. Fontana · A.Padella · V. Guadagnuolo · N. Testoni · C. Baldazzi · F. Brera · G. Martinelli

ASCO 2016, J Clin Oncol 34, 2016 (suppl; abstr e18235)

- **Impact on survival of catastrophic karyotype events in 101 consecutive Acute Myeloid Leukemia (AML) patients: high risk karyotype and chromothripsis**

Fontana MC, Marconi G, Papayannidis C, Guadagnuolo V, Lo Monaco S, *Tenti E*, Ghelli A, Simonetti G, Abbenante MC, Parisi S, Paolini S, Sartor, Padella A, Soverini S, Manfrini M, Testoni N, Baldazzi C, Martinelli G

ASCO 2016, J Clin Oncol 34, 2016

- **Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT)**

G. Marconi · C. Papayannidis · F. Mosna · M. Gottardi · *E. Tenti* · E. Franchini · A. Ghelli Luserna di Rorà · E. Ottaviani · M. C. Fontana · G. Simonetti · V. Guadagnuolo · M. Manfrini · D. Capelli · P. Galieni · A. Piccin · G. Visani · F. Rodeghiero · C. Tecchio · F. Gherlinzoni · G. Martinelli

ASCO 2016 J Clin Oncol 34, 2016 (suppl; abstr e18520)

- **Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML).**

E. Franchini · C. Papayannidis · G. Marconi · A.Ghelli Luserna di Rorà · G. Simonetti · V. Guadagnuolo · A. Padella · V. Robustelli · E. Zuffa · M. C. Abbenante · C. Venturi · M. Manfrini · S. Parisi · S. Paolini · C. Sartor · S. Lo Monaco · *E. Tenti* · M. C. Fontana · E. Ottaviani · G. Martinelli

ASCO 2016 Volume: J Clin Oncol 34, 2016 (suppl; abstr e18521)

- **Enos polymorphisms and clinical outcome in advanced hcc patients receiving sorafenib: final results of the EPHAS study**

Gardini, AC; Marisi, G; Faloppi, L; Scarpi, E; Foschi, FG; Iavarone, M Lauletta, G; Corbelli, J; *Tenti, E*; Facchetti, F; della Corte, C; Tamperi, S; Cascinu, S; Scartozzi, M; Amadori, D; Nanni, O; Ulivi, P; Frassinetti, GL
Digestive and liver disease Volume: 48 Supplement: 1 Pages: E23-E23 FEB 10 2016

- **Endothelial nitric oxide synthase(eNOS) polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Final results of ePHAS study**

Gardini, AC; Marisi, G; Ulivi, P; Faloppi, L; Scarpi, E; Scartozzi, M; Foschi, FG Iavarone, M; Lauletta, G; Corbelli, J; *Tenti, E*; Facchetti, F; Tamperi, S; Nanni, O; Cascinu, S; Amadori, D; Frassinetti, GL

- **Pharmacological Interaction in Oncohaematology: final study results**

Tenti E., Brera F, Lega N., Saibene G.

XXIV National Workshop. Drug use and safety: Italian experiences.

Istituto Superiore di Sanità, At ISS, Rome, ISSN: 0393-5620

- **Effectiveness of dermatologic evaluation in the management of cancer patients**

Medri M., *Tenti E.*, Andreis D., Scarpi E., Amadori D., Stanganelli I.

ASCO (American Society of Clinical Oncology) 2015, Volume: J Clin Oncol 33:5s, 2015 (suppl; abstr e20651)

- **Medication reconciliation in oncology and monitoring of preventable drug interactions**

Tenti E., Schirone A., Passardi A., Casadei Gardini A.

International Journal of Molecular Medicine 36 (supplement):S26 · October 2015

- **Medication reconciliation in cancer day hospital**

Tenti E., Casadei Gardini A., Schirone A., Passardi A., Minguzzi M., Prati E., Amadori D.

ASCO 2015 Volume: J Clin Oncol 33:5s, 2015 (suppl; abstr e17748)

- **eNOS Polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib**

A. Casadei Gardini, G. Marisi, *E. Tenti*, E. Scarpi, M. Scartozzi, S. Tamperi, F. Giovanni Foschi, E. Tamburini, P. Ulivi, S. Cascinu, G. L. Frassinetti –

Oral presentation: Conference *ASCO Gastroenterology* S. Francisco Jan, 2015

- **eNos polymorphism in relation to outcome in advanced HCC patients receiving sorafenib**

E. Tenti, A. Casadei Gardini, G. Marisi

XXIII National Seminar, Istituto Superiore di Sanità, Roma; 12/2014

- **Intake of alternative medicine during cancer treatment and possible drug interactions**

E. Tenti, A. Casadei Gardini, S. Cumerò, M. Minguzzi, F. Foca, D. Amadori

J Clin Oncol 32, 2014 (suppl; abstr e13540)

- **Retrospective Evaluation of Polymorphisms of Angiogenesis in Patients Treated with Sorafenib**

Tenti, E.; Gardini, A. Casadei; Marisi, G.; Scarpi M.

DRUG SAFETY Volume: 37 Issue: 10 Pages: 834-835 OCT 2014

- **Suspension of anti EGFR therapy for skin toxicity and reporting of suspected adverse reaction**

E. Tenti, A. Casadei Gardini, I. Stanganelli, M. Medri,

Drug Safety 2013 suppl; abstr ISP3506-4

- **Multicentric survey on dose reduction of cancer drugs' therapy: detection and measurement of critical phenomena as potential indicators suspected adverse reactions"**

E. Tenti, A. Casadei Gardini, D. Amadori, P. Fiacchi, A. Stancari, A. Zanardi, C. Cherubini, S. Sferra, S. Sara, C. Rondoni, A. Maugeri, S. Restuccia, M. L. Gallani, S. Palazzini, E. Bianchini, S. Menozzi, M. Minguzzi

J Clin Oncol 31, 2013 suppl; abstr e13579

- **Skin necrosis by infusion intra- arterial of chemotherapy**

M. Medri; *E. Tenti*; S. Sarti; C. D'Acunzio; C. Orlandi; D. Melandri, I. Stanganelli

Oral Presentation: Congress *ADOI SIDEMAST* E. Romagna, Nov. 2014

- **Dermal toxicity in patients treated with vemurafenib**

Medri M, **Tenti E**, Della Luna C, Mazzoni L, Magi S, De Rosa F, Ridolfi L. , Stanganelli I – *Oral presentation: IMI 2014*

- **Paclitaxel and skin toxicity in patients with breast cancer**

Tenti E, Medri M, Crociani M., Casadei Gardini A. –

Abstr. EURODURG 2014 Gronigen

- **Monitoring of cutaneous toxicity induced by antiEGFR**

Tenti E, Casadei Gardini A., Medri M.

Abstr. XXXV Congress of Hospital Pharmacists, 17 oct 2014

- **Potential drug interactions in cancer patients**

Lonzardi C, **Tenti E**, Casadei Gardini A, Calderoni D, Pieraccini F.

Abstr. XXXV Congress of Hospital Pharmacists, 17 oct 2014

- **Pharmacovigilance Activity and analysis of adverse drug reactions at IRST IRCCS in year 2013**

C. Della Luna, P. Silimbani, **E. Tenti**, A. Maueri, S. Antaridi, C. Donati, V. Di Iorio, C. Masini, F. Scardovi, M. V. Minguzzi

Abstr. XXXV Congress of Hospital Pharmacists, 17 oct 2014

- **Active Pharmacovigilance of emesis induced by injection therapy for breast cancer in oncology Day Hospital of Five Italians Hospital**

E. Tenti, N. Jannitti, F. Brera, M. Bulzacchelli, C. Rizzo,

The Italian Journal of Clinical Pharmacy, 27, 3-4, 2013

- **Therapeutic education of patients on good use of medication**

E. Tenti, C. Donati, V. Ravaioli, A. Conficconi, A. Casadei Gardini, S. Sarti, M. A. Berardi, F. Ruffilli, M. P. Braghiesi, C. Nanni, M. Minguzzi,

The Italian Journal of Clinical Pharmacy, 27, 3-4, 2013

- **Computerization optimization for a survey on adverse drug reactions at IRCCS IRST**

E. Tenti, A. Casadei Gardini, C. Della Luna, M. Minguzzi,

The Italian Journal of Clinical Pharmacy, 27, 3-4, 2013

I authorize the treatment of my personal data according to D.lgs 196 30th jun 2003 and GDPR 679/16.